117 related articles for article (PubMed ID: 12610502)
1. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer.
Noguchi M; Kikuchi H; Ishibashi M; Noda S
Br J Cancer; 2003 Jan; 88(2):195-201. PubMed ID: 12610502
[TBL] [Abstract][Full Text] [Related]
2. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment.
Yahara J; Noguchi M; Noda S
BJU Int; 2003 Sep; 92(4):379-83; discussion 383-4. PubMed ID: 12930424
[TBL] [Abstract][Full Text] [Related]
3. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
4. Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases.
Nakashima J; Kikuchi E; Miyajima A; Nakagawa K; Oya M; Ohigashi T; Murai M
Urol Int; 2008; 80(2):129-33. PubMed ID: 18362480
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.
Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi J; Kondo K; Moriyama M; Takebayashi S; Yokomizo Y; Yao M; Uemura H; Noguchi K
BMC Cancer; 2016 Feb; 16():128. PubMed ID: 26896160
[TBL] [Abstract][Full Text] [Related]
6. [Studies on prognosis of prostate cancer with bone metastasis by using pretreatment bone scintigraphy].
Kubota Y; Numasawa K; Suzuki H; Kakizaki H; Suzuki K
Hinyokika Kiyo; 1989 Oct; 35(10):1693-9. PubMed ID: 2610178
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
8. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer.
Mitsui Y; Shiina H; Yamamoto Y; Haramoto M; Arichi N; Yasumoto H; Kitagaki H; Igawa M
BJU Int; 2012 Dec; 110(11 Pt B):E628-34. PubMed ID: 22788759
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
Tucci M; Mosca A; Lamanna G; Porpiglia F; Terzolo M; Vana F; Cracco C; Russo L; Gorzegno G; Tampellini M; Torta M; Reimondo G; Poggio M; Scarpa RM; Angeli A; Dogliotti L; Berruti A
Prostate Cancer Prostatic Dis; 2009; 12(1):94-9. PubMed ID: 18332901
[TBL] [Abstract][Full Text] [Related]
10. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
11. Capromab Pendetide imaging of prostate cancer.
Haseman MK; Rosenthal SA; Polascik TJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.
Sabbatini P; Larson SM; Kremer A; Zhang ZF; Sun M; Yeung H; Imbriaco M; Horak I; Conolly M; Ding C; Ouyang P; Kelly WK; Scher HI
J Clin Oncol; 1999 Mar; 17(3):948-57. PubMed ID: 10071289
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
Kageyama Y; Kihara K; Kamata S; Nagahama K; Yonese J; Fukuda H; Tosaka A; Nagamatsu H; Ishizaka K; Tsujii T; Kitahara S; Morita T; Oshima H
Hinyokika Kiyo; 1996 Mar; 42(3):197-9. PubMed ID: 8619388
[TBL] [Abstract][Full Text] [Related]
14. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and prognostic factors for patients with bone metastases from prostate cancer.
He J; Zeng ZC; Yang P; Chen B; Jiang W; Du SS
Asian J Androl; 2012 May; 14(3):505-8. PubMed ID: 22504872
[TBL] [Abstract][Full Text] [Related]
16. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
Petrioli R; Rossi S; Caniggia M; Pozzessere D; Messinese S; Sabatino M; Marsili S; Correale P; Salvestrini F; Manganelli A; Francini G
Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
19. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
Taue R; Kanayama H; Kagawa S
Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
[TBL] [Abstract][Full Text] [Related]
20. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
